stem cells - versus placebo - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.53 [0.01, 27.55]< 10%1 study (1/-)62.0 %NAnot evaluable crucial-
deaths 0.53 [0.01, 27.55]< 10%1 study (1/-)62.0 %NAnot evaluable crucial-

safety endpoints 00

serious adverse events 1.08 [0.04, 32.96]< 10%1 study (1/-)48.3 %NAnot evaluable important-
adverse events 0.88 [0.38, 2.03]< 10%1 study (1/-)61.7 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.